Genmab — Januar 2018
-
Ny car-t med unprecedented durability of response https://myelomaresearchnews.com/2018/01/19/multiple-myeloma-phase-1-trial-car-t-cell-therapy-p-bcma-101-poseida-doses-first-patient/?utm_source=Myeloma+List&utm_campaign=9bd6b3c4f5-RSS_WEEKLY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_14fcd0022a-9bd6b3c4f5-72491777
-
Lidt om forventninger til JnJ tirsdag.https://www.barrons.com/articles/johnson-johnsons-earnings-are-coming-heres-what-to-watch-1516651968?mod=yahoobarrons&ru=yahoo&yptr=yahoo
-
Seeking Alfa mener,at der er gode muligheder for, at de slår estimaterne igen igen. Jeg kigger mest på kursudviklingen, der jo ikke har noget som helst fælles med Genmab udvikling. I dag lukker JNJ i højeste kurs nogensinde. Tirsdag var kursen en anelse højere intra dag. De dage/preioder, hvor Genmabs kurs er gået i hullet, er JNJs kurs steget. Alene ugen, 16.- 23. oktober, hvor Gen faldt fra toppen, her steg JNJ fra kurs 136 til 144. Nu er JnJ vanen tro nået ATH igen igen igen.
-
God morgen.
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind